SCHEDULE 13D/A 0001140361-20-029595 0001425851 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 01/08/2025 false 0001661460 73730P108 Poseida Therapeutics, Inc.

9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121

Matthew Halbower 239-384-9750 Pentwater Capital Management LP 1001 10th Avenue South, Suite 216 Naples FL 34102 0001425851 N Pentwater Capital Management LP OO N DE 0.00 0.00 0.00 0.00 0.00 N 0 IA PN Y Matthew Halbower OO N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN HC Common Stock, par value $0.0001 per share Poseida Therapeutics, Inc. 9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121 This Amendment No. 3 ("Amendment No. 3") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on December 28, 2020 (the "Original Schedule 13D", and the Original Schedule 13D as amended, the "Schedule 13D"). This Amendment No. 3 supplements Items 4 and 6 and amends and restates Item 5(a)-(c), and (e) as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D. Pursuant to the terms of the Pentwater Support Agreement, the Pentwater Funds tendered the shares of Common Stock beneficially owned by them in the Tender Offer. The Tender Offer expired as scheduled at one minute following 11:59 p.m., New York City time, on January 7, 2025. The shares of Common Stock held by the Pentwater Funds were accepted for payment on January 8, 2025. As a result, the Reporting Persons no longer own, beneficially or otherwise, any securities of the Issuer. In addition, on January 8, 2025, following consummation of the Tender Offer, Merger Sub merged with and into the Issuer, with the Issuer being the surviving corporation (the "Merger"). Accordingly, at the effective time of the Merger, the Pentwater Support Agreement terminated pursuant to its terms. See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by each Reporting Person. See rows (7) through (10) of the cover page to this Schedule 13D for the shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. Except as disclosed in Item 4, there have been no transactions effected by the Reporting Persons during the past sixty (60) days. January 8, 2025. As a result of the closing of the Merger, the Cash Derivative Agreements held by the Pentwater Funds at the time of closing of the Merger settled in accordance with their terms based on the Offer Consideration as defined in the Merger Agreement. Pentwater Capital Management LP /s/ Matthew Halbower 01/13/2025 Matthew Halbower /s/ Matthew Halbower 01/13/2025